The current estimate is that the risk of AD is reduced by about 40% if modifiable risk factors including cardiovascular disease, obesity and diabetes were eliminated (Livingston et al., 2020). Recent reviews (Mielke, 2018; Rahman et al., 2019) pinpoint a sex dimension in several risk factors (see Table 1) including level of education and social interaction, smoking, alcohol consumption and stress may also have a sex-related component (Podcasy and Epperson, 2016; Yan et al., 2018).

Exercise and diet are among the strategies that can have a far reaching impact on a number of modifiable AD risk factors. A study of 44,000 individuals with a 10 year follow-up period provided convincing evidence that disabling dementia in both men and women was inversely proportional to daily physical activity (Ihira et al., 2022) but both aerobic and resistance training appear to improve executive function to a greater extent in women (Barha et al., 2017). Moreover, the association between physical and cognitive ability and memory reserve is stronger in women than men and this is influenced by APOE4 (Pa et al., 2022). While a scientific basis for this remains to be determined, evidence from animal studies suggests that sex-related differences in exercise-stimulated growth factors, brain architecture and/or cardiac or respiratory responses may play a role (Barha and Liu-Ambrose, 2018).

Adiposity is a confirmed risk factor for AD (Deng et al., 2022) and some evidence points to it driving inflammation to a greater extent in females compared with males (Khera et al., 2009) although gray matter volume decreases to a greater extent in obese males compared with females, suggesting that obese males may be at greater risk of later cognitive decline (Taki et al., 2008). Diet also appears to have sex-dependent effects with evidence that adherence to a Mediterranean diet exerts a greater benefit (Gregory et al., 2022), and greater protection against AD (Rahman et al., 2019), in women.

The evidence is that menopause constitutes a risk of AD and it has been reported that the reduction in brain glucose metabolism that occurs with the menopause is linked with prodromal AD and, indeed, it has been proposed that early estrogen therapy may be a useful strategy in reducing the menopause-associated risk of AD (Mosconi and Brinton, 2018; Mosconi et al., 2018; Mishra et al., 2022).

Despite heterogeneity in evaluating educational achievement, a recent review concluded that the evidence linking poorer education and increased risk of AD was robust (Maccora et al., 2020). The fact that education was more limited for women than men in the past opened up the possibility that this contributed to the greater risk of AD in women (Bloomberg et al., 2021; Gong et al., 2023) and a recent analysis of 2 prospective studies has suggested that females may benefit more from education than men in terms of AD risk (Bloomberg et al., 2021).

APOE is the greatest genetic risk factor for sporadic AD and the ε4 allele confers the greatest risk (Corder et al., 1993; Strittmatter et al., 1993) although many additional susceptibility genes, particularly related to amyloid, tau, immunity, lipids and endocytosis, have been identified by Genome-wide association studies (GWAS) (Bellenguez et al., 2022). Genes that confer significant risk of AD include TREM2, BIN1, PICALM, CLU and CR1.

Sex-related differences in the responses of AD patients to cholinesterase inhibitors have been reported but data are limited with few studies explicitly analyzing the impact of sex on treatment outcomes as pointed out in recent reviews (Canevelli et al., 2017; Mehta et al., 2017). Mehta et al. (2017) evaluated 33 studies in which sex was considered as a demographic variable, sex-stratified data were reported in only 1 study where no difference was identified. Canevelli et al. (2017) reported that only 2 out of the 48 randomly-controlled trials specifically assessed sex differences and these reported no sex-related differences in cognition in response to donepezil, corroborating the findings of an earlier review which concluded that sex exerted a minimal impact on the effects of cholinesterase inhibitor efficacy in spite of evidence from animal studies (Haywood and Mukaetova-Ladinska, 2006).

The studies that analyzed the effect of sex are mostly small in scale and date back >10 years. One of the more recent studies assessed the effect of donepezil, rivastigmine and galantamine in a 3-year prospective study and reported that the decline in cognitive function, at least in the short term, was slower in cholinesterase inhibitor-treated individuals compared with controls and that efficacy was better in older persons and non ε4 carriers. Overall the response was better in males than females but data were not stratified and whether sex differences were observed for all 3 drugs is unclear (Wattmo et al., 2011).

Earlier investigations reported that donepezil-treated male AD patients performed better in the Boston Naming Test than females (Davis and Barrett, 2009), supporting earlier findings that reported greater efficacy of cholinesterase inhibitors in male AD patients (MacGowan et al., 1998). In contrast, others observed that women AD patients responded better to donepezil and rivastigmine than men, exhibiting less marked cognitive decline (Scacchi et al., 2014), and that rivastigmine delayed progression from MCI to AD in females but not males (Ferris et al., 2009). These inconclusive findings are reflected in data from preclinical studies where donepezil preferentially improved cognitive function in male rhesus monkeys (Buccafusco et al., 2003) while rivastigmine antagonized scopolamine-induced spatial memory to a greater extent in female rats (Wang et al., 2000).

Variables that may contribute to a sex difference in response to these drugs include the influence of sex hormones and sex-related differences in the cholinergic system (Yoshida et al., 2000; Moen and Lee, 2021; Bennett et al., 2022). APOE genotype may also exert an impact. It was shown that female, but not male, ε2/ε3 carriers with mild-to-moderate AD responded better to tacrine than ε4 carriers (Farlow et al., 1998) and that tacrine improved cognitive function in male ε4 carriers more than male non-carriers and female ε4 carriers (MacGowan et al., 1998), but others reported that while ε4 carriers responded better to tacrine, there was no impact of sex (Rigaud et al., 2000). The therapeutic response to donepezil may also be affected by APOE genotype with evidence suggesting that ε4 carriers respond better (Choi et al., 2008); the effect of sex was not reported in this study.

To my knowledge, sex-related differences in efficacy to memantine have not been studied although palability issues have been reported in women (Ruiz et al., 2019). Analysis in 3xTg mice revealed that 3 months treatment with memantine increased plasma concentration and decreased Aβ oligomers to a greater extent in females than males but improved cognition and decreased tau and Aβ plaques similarly in male and female mice (Martinez-Coria et al., 2010).

Aducanumab, an Aβ-directed monoclonal antibody that binds to aggregated Aβ and recognizes amyloid plaques in brain, was the first immunotherapy that received US Food and Drug Administration (FDA) approval. Sex-related differences were not described in several published papers/commentaries that reported on the findings in the aducanumab trials ENGAGE or EMERGE (Knopman et al., 2021; Kuller and Lopez, 2021; Sabbagh and Cummings, 2021; Budd Haeberlein et al., 2022; Schneider, 2022; Rahman et al., 2023) even though policy suggests that appropriate recognition is given to this issue.

Lecanemab, which selectively binds to large soluble Aβ protofibrils, was approved in July 2023. Patients receiving lecanemab for 18 months showed a slower progression of disease, with reduced Aβ and better cognition compared with untreated patients (Swanson et al., 2021). The benefits were reported to be greater in men than women (van Dyck et al., 2023) reflecting data obtained in the Thy-Tau22-5xFAD (T5x) mouse model in which the decrease in soluble and insoluble Aβ was greater in brain tissue of male mice compared with females (Davtyan et al., 2019). The efficacy of lecanemab was greater, and the risk of amyloid-related imaging abnormalities (ARIA) was significantly reduced, in APOE4 non-carriers compared with carriers. However, the data originally presented by van Dyck and colleagues in 2023 were recently reassessed and it was concluded that the impact of lecanemab was less than reported, and was ineffective in females (Kurkinen, 2023).

Agents designed to target different neurotransmitters include those acting on the cholinergic system (different formulations of the cholinesterase inhibitors donepezil and huperzine A, the cholinergic antagonist mecamylamine, choline alfoscerate that may increase brain ACh levels and the nicotine patch designed to directly activate nicotinic receptors), the NMDA receptor (memantine and other agents with antagonist action, SAGE-718, AVP-786, AXS-05, huperzine A, Chinese “Smart soup”), the β2-adrenergic receptor agonist CST-2032, and the sigma-2 receptor antagonist, CT1812.

Several agents are being investigated for their effectiveness in controlling AD-related agitation; these include agonists at cannabinoid receptors (cannabidiol, dronabinol and IGC-AD1), α2 adrenergic receptors (gabapentin) and D2 receptors (brexpiprazole), and NMDA receptor antagonists, AXS-05, AVP-786 and “Smart soup”. Agonists and antagonists at different 5-HT receptors (masupirdine, a 5HT-6 receptor antagonist; piromelatine, a 5-HT-1A/1D receptor agonist as well as acting on melatonin MT1/2/3) and the selective serotonin reuptake inhibitor, escitalopram, are also in trial for treating agitation, while trazodone (agonist and antagonist activities at different 5HT receptors), is in trial for AD-related insomnia. Orexin receptor type 2 antagonists (Lemborexant, seltorexant and suvorexant) are also in trial for insomnia and KarXT (M1 receptor agonist) is in trial for the treatment of psychosis.

Clearly, sex-related differences in receptor density or receptor-related signaling opens the possibility that there may be differences in drug efficacy between males and females. Findings, mainly from preclinical studies, suggest that sex hormones influence expression and/or signaling of several receptors (Wilbert-Lampen et al., 2005; Kritzer and Creutz, 2008; Normandin et al., 2015; Bangasser et al., 2016), while sex-related differences in cholinergic activity (Giacobini and Pepeu, 2018) and NMDA receptor function (Wickens et al., 2018; Giacometti and Barker, 2020; Knouse et al., 2022) have been described. There are sex differences in gene expression in noradrenergic receptors (Mulvey et al., 2018) and in circuitry (Sun et al., 2020), and in 5HT transmission, concentration, metabolism and receptor expression (Cosgrove et al., 2007; Sramek et al., 2016; Songtachalert et al., 2018). Analysis of serotonin synthesis by PET using α-[¹¹C]methyl-L-tryptophan as a tracer revealed that synthesis was 50% higher in the brains of males compared with females (Nishizawa et al., 1997). Sexual dimorphisms in dopamine receptor expression have also been reported (Williams et al., 2021) with recent metanalysis demonstrating greater binding of the selective D₂R antagonist [¹¹C]raclopride in putamen and caudate of females compared with males (Malén et al., 2022). Sex-related differences in the orexin system (Grafe and Bhatnagar, 2020), and cannabinoid receptors (Rubino and Parolaro, 2011; Normandin et al., 2015) and sigma receptors (Smith et al., 2018), have also been reported. It must be predicted that such differences are likely to significantly affect the efficacy of drugs that target these neurotransmitter receptors or pathways and provide a strong argument in favor of sex subgroup analysis and reporting in clinical trials.

Strategies designed to reduce Aβ remain at the heart of discovery in the context of AD. There are several ongoing clinical trials using antibodies that target specific epitopes of Aβ (Song et al., 2022) designed to reduce Aβ burden, including additional trials on the already-licensed aducanumab and lecanemab.

Donanemab, for which a decision from the FDA is expected in 2024, binds to the pyroglutamate-modified, N-terminal form of Aβ that is present in plaques. It retards progression of the disease and decreases Aβ plaques (Mintun et al., 2021; Reardon, 2023a) particularly in those with less tau pathology (Sims et al., 2023). Minimal attention has been paid to assessment of potential sex-related differences in the efficacy of donanemab although one paper suggested that sex did not impact on disease progression rates (Gueorguieva et al., 2023). As in the case of lecanemab, the risk of ARIA was greater in APOE4 carriers compared with non-carriers.

Among others in trial are solanezumab, which targets the mid-domain of the Aβ peptide and recognizes soluble monomeric Aβ (Doody et al., 2014; Honig et al., 2018), crenezumab, which binds to stable oligomers and inhibits aggregation of Aβ (Ostrowitzki et al., 2022), ganteneumab, which binds to a conformational epitope on Aβ fibrils (Bateman et al., 2022). Data from a phase 2 trial with solanezumab suggested that there may be some sex differences in antibody distribution but this was not further investigated (Farlow et al., 2012). To my knowledge, there are no published data on sex-related differences in distribution, efficacy or pharmacodynamics on any other monoclonal antibody, except lecanemab (see above).

Targeting the N-terminal pyroglutamate Aβ epitope increases microglial-mediated phagocytosis of Aβ (Crehan et al., 2020) and therefore there are an increasing number of antibodies designed to exploit this including ABBV-916 and remternetug, which are currently in phase 2 and 3 trials respectively. Varoglutamstat (PQ912) also reduces production of pyroglutamate Aβ by inhibiting glutaminyl cyclase and is in phase 2 trials. In combination with a mouse pyroglutamate-3 Aβ antibody, it reduced Aβ accumulation and improved cognitive function, in APP/PS1 mice (Hoffmann et al., 2017). Targeting pyroglutamate-modified pE₃Aβ in the 5XFAD mouse model of AD reduced pyroglutamated and non-pyroglutamated Aβ plaques in male and female mice. Highlighting a sexual dimorphism, soluble Aβ was decreased only in male mice whereas insoluble Aβ was decreased only in female mice (Zagorski et al., 2023). Of course, there is no guarantee that the sex differences identified in mice will translate into humans, but the fact that there are indications of sex-related responses to lecanemab and solanezumab presents a forceful argument for stratification by sex in all clinical trials.

Other approaches to interfere with Aβ accumulation are being investigated, including small molecules designed to prevent oligomer formation, or to block the impact of these oligomers. For instance, ALZ-801, described as anti-oligomer and as an aggregation inhibitor, is currently in phase 2 trials, as is CT1812, a sigma-2 receptor allosteric antagonist, designed to inhibit binding of Aβ oligomers to oligomer receptors thereby reducing Aβ-induced synaptic toxicity. Autoradiographic analysis has shown sex-related differences in sigma 2 receptors binding and suggested that a reduction in receptors is associated specifically with Aβ pathology specifically in female APP/PS1 mice (Sahlholm et al., 2015).

Buntanetap reduces Aβ by inhibiting APP synthesis (Fang et al., 2023) and is currently in phase 2 trials. It improved cognition in APP/PS1 mice and improved synaptic function (Teich et al., 2018) but only female mice were investigated. To date, trials targeting γ-secretase have been unsuccessful (Yiannopoulou et al., 2019) but newer agents have shown some promise (Rynearson et al., 2021). Many trials on BACE1 inhibitors have also been unsuccessful but new classes of drugs that modulate BACE1 activity are in development (Monteiro et al., 2023). It is worth noting that sex differences in γ-secretase and BACE1 have been reported in mice, Increased activity of γ-secretase and increased expression of nicastrin and presenilin have been reported in tissue from 24 month-old female mice (Placanica et al., 2009), while estrogen downregulates BACE1 transcription (Cui et al., 2022). It is also interesting that circulating BACE1 concentrations were significantly higher in a cohort of females compared with males that were at risk of AD (Vergallo et al., 2019).

Agents in clinical trials aimed at modulating tau are mainly monoclonal antibodies and inhibitors of tau aggregation. Monoclonal antibodies that are currently in trial include Lu AF87908, which recognizes phosphorylated tau (p-tau) protein, APNmAb005, which recognizes a conformational epitope in tau oligomers and JNJ-63733657 and E2814 which recognize the microtubule binding region of tau. The epitope to which E2814 binds, plays a role in seeding and propogation, and is a predominant component of tau tangles (Roberts et al., 2020). Tau-targeting antisense oligonucleotides, NIO752 and BIIB080, that inhibit translation of tau mRNA into the tau protein, and drugs designed to inhibit tau aggregation/self-association LY3372689, TRx0237 and OLX-07010 are also in clinical trial as is nicotinamide riboside, which has been shown to decrease tau phosphorylation (Hou et al., 2018), attenuate cognitive deterioration and improve synaptic plasticity in mouse models of AD (Gong et al., 2013; Hou et al., 2018).

To my knowledge, there are no published reports of sex-related differences in responses to such agents although it is well documented that there are marked differences in tau accumulation in males and females, with greater tau accumulation in brains of female AD patients compared with males (Oveisgharan et al., 2018). A recent study designed to assess tau propagation using regional [¹⁸F]flortaucipir PET analysis suggested a more widespread increase of tau in female MCI patients compared with males (Shokouhi et al., 2020) and it was shown that naturally-occurring tau antibodies were lower in CSF from female AD patients compared with males (Krestova et al., 2018). Even in cognitively-intact elderly individuals, the age-related increase in p-tau in postmortem brain tissue is enhanced to a greater extent in women than men (Hu et al., 2021). Tau has been coupled with sex-specific genetic variants in men and women that are linked with enhanced risk of AD. SNPs within DNAJA2, FERMT2, and TYW5 were associated with tau in women whereas SNPs within CR1 were associated with Tau in men (Wang X. et al., 2022).

In the absence of clinical data, the findings of preclinical studies that identified sexual dimorphism related to tau are worthy of note. The recombinant protein/tau vaccine AV-1980R, which induces antibodies that inhibit tau aggregation, decreased soluble p-tau in the brains of male and female T5x double transgenic mice but its effect on insoluble p-tau was confined to male mice (Davtyan et al., 2019).

The burgeoning volume of data that implicates perturbation in the immune system and microglial function has triggered a search for agents that modulate both in the hope of altering the course of AD. GWAS has identified polymorphisms in several genes that code for proteins involved in immune function and endow significant risk of AD. One is TREM2 (Guerreiro et al., 2013; Jonsson et al., 2013), which is expressed on microglia and is essential for the clustering of microglia around amyloid plaques (Jay et al., 2017; Lewcock et al., 2020). There is evidence that TREM2 is protective (Zhao et al., 2017; Brown and St George-Hyslop, 2021) as is soluble TREM2, which binds Aβ, prevents its oligomerization and improves cognition in a mouse model of AD (Zhong et al., 2019; Sheng et al., 2021). Consistently, knocking out TREM2 resulted in greater plaque burden; this effect was greater in female mice compared with males (Meilandt et al., 2020). APOE genotype, as well as sex, affects the TREM2-mediated interaction between plaques and microglia. Microglial-plaque interaction correlated with TREM2 expression and was approximately 5 times higher in 5xFAD/APOE3^+/+ male, compared with female, mice and markedly reduced in 5xFAD/APOE4^+/+ female mice (Stephen et al., 2019).

Clinical trials on AL002, an antibody targeting TREM2, are ongoing and a second antibody, DNL919, has been placed on clinical hold while further assessment of its safety/toxicity is investigated. These trials make no specific reference to analysis of sex-related differences though this is clearly relevant given the available preclinical data.

Other drugs in clinical trials that are designed to modulate microglia include sodium oligomannate (GV-971), mastinib and the CSF1R antagonist JNJ-40346527. Another CSF1R antagonist, PLX3397, has been assessed in a clinical trial but the EU Clinical Trials Register reports that the trial was ended prematurely. However because its action is similar to that of JNJ-40346527, it is relevant to consider the data which indicate that PLX3397 exerts sex-dependent effects. It depleted microglia to a greater extent in female, compared with male, rats (Sharon et al., 2022) and, in Tg2541 mice, it decreased tau, and extended the life span of female, but not male mice (Johnson et al., 2023). It was further shown that plasma and brain PLX3397 levels were increased to a greater extent in male, compared with female, mice indicating that sex impacts on PLX3397 pharmacokinetics. This suggests that PLX3397 treatment should be tailored to sex to ensure benefit in males and females, in mice in the first instance.

Masitinib modulates microglia probably through inhibition of the M-CSF receptor kinase 1, although it also inhibits the tyrosine kinases c-kit, fyn and lyn, and PDGF and FGF receptors. Analysis in cancer patients has identified sex-related differences in pharmacokinetics and, in particular, slower elimination of tyrosine kinase inhibitors in females (Huang et al., 2022; Özdemir et al., 2022). Other inhibitors of tyrosine kinases that are also in clinical trial for the treatment of AD include dasatinib, a potent inhibitor of Abl and Src and the JAK inhibitor, baricitinib (Matsushita et al., 2023), although sex-related differences in the pharmacokinetics of these have not been reported.

Semaphorin 4D and galactin 3 redirect microglia toward an inflammatory phenotype (Smith et al., 2015; Tan et al., 2021) and are upregulated in AD (Tan et al., 2021; Evans et al., 2022); antibodies directed at both are currently in Phase 1 and/or 2 trials. There is some evidence of a sexual dimorphic effect of galactin 3 in mouse models of stroke (Mijailović et al., 2022). Daratumumab, a CD38 antibody is also being assessed as a potential disease-modifying strategy in AD since CD38 also modulates microglial activation and has been shown to enhance Aβ accumulation (Blacher et al., 2015).

Mutations in the gene encoding sortilin1 have been linked with increased risk of AD and an anti-sortilin 1 antibody, AL-001, is currently in clinical trials for AD. One mutation, SORL1 SNP 4 (rs661057), is associated with an increased risk of AD in women (Cellini et al., 2009).

Other agents in clinical trials designed to impact on microglia and reduce neuroinflammation include those that aim to reduce inflammatory cytokines, or the impact of these cytokines, like lenalidomide (Valera et al., 2015), L-serine (Ye et al., 2021) and XPro1595 (MacPherson et al., 2017) and, at least in the case of XPro1595, its modulatory effects on stress-induced inflammatory changes were shown to be sex-dependent (Eidson et al., 2019). The antiretroviral agent, lamivudine, which improves age-related cognitive function and modulates genes related to the Type 1 interferon response (Li et al., 2021), is currently in early phase trials and is known to exert sex-related effects (Anderson et al., 2003). The cannabinoids, SCI-100 and palmitoylethanolamide (Landucci et al., 2022), are also in clinical trial because of their reported anti-inflammatory action and, when assessed for the treatment of neuropathic pain, responses to palmitoylethanolamide were shown to be sex-dependent (Morera et al., 2015).

It is abundantly clear that microglial phenotype and function are markedly affected by sex with an ever-growing literature suggesting a disproportionate impact of microglial activation and inflammation in females in the context of AD (Kodama et al., 2020; Casaletto et al., 2022; Lynch, 2022). This means that particular attention should be paid to sex when agents that affect their function are in clinical use and demands that clinical trials should be designed with specific emphasis placed on specifically assessing sex-related responses to drugs.

As indicated in the paragraphs above, a significant part of the work investigating the role of inflammation in AD has been derived from animal studies. While many of these suggest that inflammation drives amyloid accumulation, there are contradictory data, perhaps arising from differences between the different models of AD, as pointed out in a recent review (Xie et al., 2021). Furthermore, it is without doubt that amyloid contributes to inflammatory changes (Wang S. et al., 2022) and therefore further study is necessary to clarify the temporal relationship between inflammation and amyloid accumulation.

Studies using positron emission tomography (PET) have reported that microglial activation, as assessed by ¹¹C-PBR28, correlates with accumulation of amyloid (¹⁸F-flutemetamol) more so in MCI, compared with tau (¹⁸F-AV1451) where the correlation is stronger in established AD (Dani et al., 2018). This indicates that an important factor in consideration of treatments that target microglial activation/inflammation is timing, which was emphasized by others who reported a “biphasic trajectory of inflammation” where the correlation between inflammation and amyloid accumulation varied with the stage of disease (Ismail et al., 2020).

Oxidative stress is a feature of AD and homocysteine concentration, which is a marker for oxidative stress, was greater in men with AD compared with women (Tenkorang et al., 2018). This is significant because a number of agents that target oxidative stress are currently in trial for AD including n-3 fatty acids, DHA and EPA, the fatty acid synthase inhibitor, CMS121, the free radical scavenger, hydralazaine hydrochloride and Flos gossypii flavonoids. Sex-related differences in responses to n-3 fatty acids have been reported in mice with DHA reducing social isolation-induced anxiety and depressive-like behaviors in male mice but not in female mice (Davis et al., 2017). In human studies, a strong positive correlation between dietary n-3 fatty acids and cognition was observed in females but not males (Lassek and Gaulin, 2011) while dietary supplementation with n-3 fatty acids improved episodic memory in females but not males (Stonehouse et al., 2013). Hydralazine hydrochloride eexerts its antioxidative effects by activating the Nrf2 pathway and the evidence indicates that sex is a variable in Nrf2 activation. Specifically, dimethylfumarate (DMF), which increases Nrf2 activation, exerted an effect in microglia prepared from the cortex of female mice but not male mice (Mela et al., 2022).

Disruption of metabolic processes are well-described features of AD and these include glucose hypometabolism (Hammond et al., 2020; Hammond and Lin, 2022) and a shift from glucose to lipid metabolism (Demarest et al., 2020). A recent analysis revealed that brain metabolism decreased over a 2 year period in women with AD, as assessed by ¹⁸F fluorodeoxyglucose-PET, and that this was correlated with circulating Aβ42:Aβ40. Further transcriptomic analysis identified that the number of differentially expressed genes, particularly those related to glucose metabolism, was 3 times greater in female, compared with male AD, patients (Park et al., 2023). Similar sex-specific differences have been reported in animal models of AD (Guillot-Sestier et al., 2021; Strefeler et al., 2023). Impaired mitochondrial function is also a recognized change in the brains of AD patients (Wang et al., 2020) and animal models of AD (Fang et al., 2019; Demarest et al., 2020) and the evidence indicates that mitochondrial metabolism is particularly compromised in female APP/PS1 mice (Demarest et al., 2020; O’Neill et al., 2022).

Unsurprisingly, a number of drugs that aim to restore metabolism are in development, and a few are in clinical trials including nicotinamide riboside and dapaglifozin, which are designed to improve mitochondrial function and reduce blood glucose by inhibiting the sodium-glucose co-transporter-2 (SGLT2). There is some evidence suggesting that SGLT2 may exert sex-specific effects (Rivera et al., 2023).

The medium chain triglyceride, tricaprilin, is also in clinical trial. It is ultimately metabolized to ketones which appear to exert beneficial effects in AD (Jensen et al., 2020) with evidence from preclinical studies indicating that ketone supplementation decreased β-hydroxybutyrate and increased blood glucose in older female rats and had the opposite effect in male rats, while body weight increased to a greater extent in males (Kovács et al., 2020). Interestingly, in TBI, the protective effect of β-hydroxybutyrate appears to be confined to males (Greco et al., 2020).

Type 2 diabetes confers a significant risk of developing AD and a recent study that analyzed data from 450,000 individuals determined that females with type 2 diabetes had a higher risk of developing AD than men with type 2 diabetes (Zhou et al., 2023). Significantly, the evidence suggests that type 2 diabetes is more prevalent in women than men (Ashraf et al., 2021). Type 2 diabetes and AD share similarities, particularly insulin resistance (Arnold et al., 2018). These similarities and the evidence from animal studies demonstrating that intranasal insulin improved cognition in APP/PS1 mice (Mao et al., 2016) and also in 3xTg AD mice, aged animals and Aβ-treated animals (Ohyagi et al., 2019), triggered an interest in assessing insulin as a potential therapy in AD. Intranasal insulin was reported to exert no significant effect on cognition in a recent study in which data from males and females were combined (Craft et al., 2020). However an earlier study reported sex-dependent effects in MCI and AD patients; improved cognitive function was observed in males but not females and the effect was greater in ApoE ε4-negative males, but not females (Claxton et al., 2013). Further studies are clearly required to gain clarity on effects and there are currently 2 trials in progress.

Other agents designed to improve insulin sensitivity and signaling are also in clinical trial, including semaglutide, a glucagon-like peptide-1 (GLP-1) agonist that enhances insulin signaling in the brain. A recent analysis of 3 large trials concluded that treatment of patients with type 2 diabetes with semaglutide or liraglutide reduced the incidence of dementia (Nørgaard et al., 2022). Although similar results were reported in males and females, sex-related differences in the effects of GLP-1 agonists have been observed; for example, weight loss, a greater decrease in glycated hemoglobin and a greater improvement in β cell function were all recorded in females (Rentzeperi et al., 2022). GLP-1 agonists were also more effective in reducing cardiovascular events in females with type 2 diabetes compared with males (Raparelli et al., 2020).

Metformin is currently in trial as a potential disease modifying agent in AD. A study in the PDAPP (J9) mouse model (AβPP mice) of AD revealed that cognitive function improved in metformin-treated, compared with control-treated female AβPP mice whereas it deteriorated in males (DiTacchio et al., 2015). There are no reports on sex-related differences in response to metformin in AD patients as highlighted recently (Chaudhari et al., 2020).